TAMPA, FL - (BUSINESS WIRE) - September 9, 2005 - Nanobac Life Sciences, Inc. (OTCBB: NNBP) ("Nanobac" or "the Company") announces the launch of its new e-commerce website, www.nanobac.com. The new site consolidates information from three Nanobac websites and features a wide array of resources, tools and interactive features. Visitors can quickly and easily gather information about the Company's products and services as well as learn more about Calcifying Nano-Particles (CNPs), also known as "Nanobacteria".
Organized by business unit, the new Nanobac website is easy to navigate, enabling visitors to find exactly what they are looking for quickly and conveniently. The categories include:
"Information on Calcifying Nano-particles or Nanobacteria is advancing quickly," stated Grant Carlson, Nanobac's President & COO. "We wanted to introduce a single site that enabled our visitors to easily find the latest information on CNPs and at the same time provide our customers a single site for doing business."
Nanobac welcomes you to visit our new site at www.nanobac.com.
Nanobac Life Sciences, Inc. is dedicated to improving people's health through the detection and treatment of Calcifying Nano-Particles, also referred to as "Nanobacteria". The Company's pioneering research is establishing the pathogenic role of Nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease.
Nanobac has identified and established two serum biomarkers of nanobacterial infection, and expects to file for FDA approval of its NanoCapture™ and Nano-Sero™ ELISA assays to detect nanobacteria antigen and IgG antibody respectively. It is also leveraging its proprietary knowledge and intellectual property to develop novel therapeutics to treat nano-particle infections. The Company currently markets a patented nanobiotic regimen and has developed tests to detect Nanobacteria in blood, serum, tissues, urine and spinal fluids. Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobac.com.
Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.